The Conversation (0)
AC Immune Announces the Selection of Tau Small Molecules for Clinical Development in Alzheimer’s disease
Apr. 05, 2018 08:46AM PST
Biotech InvestingAC Immune (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in proof-of-concept studies in Alzheimer’s disease. In addition to the Tau inhibition, a significant parallel reduction of microglia activation …
AC Immune (NASDAQ:ACIU), a Swiss-based, clinical stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in proof-of-concept studies in Alzheimer’s disease. In addition to the Tau inhibition, a significant parallel reduction of microglia activation and neuroinflammation has been observed; another key factor in Alzheimer’s and other neurodegenerative diseases.
As quoted in the press release:
Prof. Andrea Pfeifer, CEO of AC Immune, said: “AC Immune has one of the largest Tau pipelines in the industry and our various therapies intervene at key points in the pathway of Alzheimer’s disease. The specifically designed Tau Morphomers have a unique mode of action, inhibit intracellular Tau pathology the source of Tau spreading and reduce neuroinflammation. Hence, they are well-positioned to be used in mono- and combination therapies of neurodegenerative diseases.”